Extracellular Vesicles Regulate Wnt Signaling in Hepatocellular Carcinoma

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Judy YAM	--	2110	2023-04-18 17:05:58	\|
2	format correct	Conner Chen	+ 4 word(s)	2114	2023-04-19 07:48:12	\| \|
3	format correct	Conner Chen	+ 8 word(s)	2122	2023-04-19 07:51:52	\| \|
4	format correct	Conner Chen	+ 1 word(s)	2123	2023-04-24 08:44:01	\|

This entry is adapted from the peer-reviewed paper 10.3390/cancers15072088

So far, extracellular vesicles (EVs) have played an important role in the progression of multiple cancers by regulating the Wnt pathway. The regulation of Wnt signaling by Evs in hepatocellular carcinoma (HCC) is primarily achieved by modulating the classical pathway.

hepatocellular carcinoma extracellular vesicles Wnt signaling

1. EVs Regulate Wnt Signaling in HCC

So far, extracellular vesicles (EVs) have played an important role in the progression of multiple cancers by regulating the Wnt pathway. The migration of cancer cells in breast cancer is closely related to stromal mobilization, and studies have reported that this can be achieved by Wnt/planar cell polarity (Wnt/PCP) signaling regulation by EVs ^[1]. In cervical cancer-derived EVs, Wnt7b mRNA is expressed at high levels. It could be transferred to human umbilical vein endothelial cells to promote Wnt7b synthesis in recipient cells, affecting the proliferation and angiogenesis of recipient cells by regulating the β-catenin signaling, ultimately promoting tumor progression ^[2]. However, the regulation of Wnt signaling by EVs in hepatocellular carcinoma (HCC) is beginning to be researched. Current studies have found that Evs can transfer contents between different HCC cells and activate Wnt signaling, thereby regulating the biological behavior of recipient cells and promoting the progression of malignant phenotypes. In addition, stromal cell-derived Evs can also deliver contents to HCC cells and other stromal cell types. These, on the one hand, lead to HCC resistance and, on the other hand, lead to immune cells expressing more exhaustion markers and fewer effector molecules. The following contents summarizes the current status and mechanisms underlying EV regulation of Wnt signaling in HCC to help us gain a better understanding of this phenomenon and provide ideas for deriving new therapeutic strategies for HCC.

2. Evs Regulate Wnt Signaling via Transport between Different Types of HCC Cells

The regulation of Wnt signaling by Evs in HCC is primarily achieved by modulating the classical pathway. Several studies have found that Evs regulate Wnt signaling via transport between different types of HCC cells (Table 1). Solid tumor cells are often surrounded by a hypoxic microenvironment ^[3], a condition favoring metastatic tumor progression ^[4]. Yu et al. discovered that this hypoxic environment contributes to exosome production in HCC. Furthermore, exosomes secreted by hypoxic tumor cells were found to promote malignant phenotypes of normoxic cells, including their proliferation, migration, invasion, and epithelial-to-mesenchymal transition (EMT). A study of the underlying mechanisms found that miR-1273f levels increased significantly in exosomes secreted by Huh7 cells under a hypoxic environment, and recipient HCC cells showed enhanced malignancy that was closely related to this miRNA in vitro. The search for downstream targets revealed that miR-1273f functions by targeting a tumor suppressor gene (LHX6) ^[5]. Several previous studies have demonstrated that LHX6 can inhibit the progression of multiple tumor types, including glioma, lung cancer, and breast cancer. LHX6 regulates Wnt/β-catenin signaling by inhibiting β-catenin expression, thereby inhibiting tumor progression. Furthermore, this process can be reversed by the downregulation of LHX6 by miR-1273f ^[6]^[7]^[8]^[9].

Accumulating evidence suggests that via exosome-mediated material transfer, high-metastatic HCC cells can enhance the migration and invasion abilities of low-metastatic HCC cells ^[10]^[11]^[12]. An in vitro study that isolated exosomes from highly metastatic HCC cells and used them to treat low-metastatic HCC cells observed reduced apoptosis and enhanced proliferative capacity in the latter. The abilities of the recipient cells to invade and migrate were also simultaneously enhanced. Animal experiments concluded that the tumorigenic rate of mice injected with exosome-treated tumor cells increased significantly, and multiple metastases were found in the liver and lungs, suggesting enhanced tumor metastasis ability. Interestingly, high levels of miR-25 were expressed in both highly metastatic HCC cell-derived exosomes and recipient cells. Mechanistically, miR-25 activates Wnt/β-catenin signaling by reducing the expression level of serine/threonine-protein kinase 1 (SIK1) ^[13].

Yu et al. analyzed paired tumor tissues and adjacent non-tumor tissues of HCC patients, including 35 paraffin-embedded and 40 frozen specimens. They found that DEAD-box helicase 55 (DDX55) was overexpressed in HCC tissues, mainly located in the nucleus and cytoplasm. They studied its function and mechanism and found that DDX55 interacted with Bromodomain-containing protein 4 (BRD4) to form a transcriptional regulatory complex that positively regulated the transcription of PIK3CA, a core gene regulating Akt and Wnt pathways. Subsequently, the PI3K/Akt/GSK-3β pathway was activated, stabilizing β-catenin and regulating the downstream gene expression, ultimately promoting cell cycle progression and EMT. On further investigation, it was noted that DDX55 could be transferred from HCC cells with relatively high DDX55 expression to those with relatively low DDX55 expression via exosomes. They also observed that these DDX55-rich exosomes could also be transferred into endothelial cells, inducing increased angiogenesis, and the underlying mechanism might be related to the activation of the β-catenin signal ^[14].

In one study, serum samples were collected from randomized healthy donors, patients with chronic HBV infection, and patients with liver disease (cirrhosis, early HCC, and late HCC) without any treatment. Then exosomes were extracted from the serum. Interestingly, the researchers found that patients with late HCC had the greatest number of serum exosomes. Then they co-cultured these exosomes with Huh7 cell lines and were surprised to find that exosomes from HCC patients increased the growth and motility of Huh7 cells. In addition, exosomes derived from patients with late HCC were superior to those from cirrhotic patients and even more superior than those from patients with early HCC. This finding was linked to the promotion of malignant biological behavior of HCC cell lines by exosomes in vitro or the promotion of tumor formation and metastasis in orthotopic liver transplantation models in vivo. The research focused on the underlying mechanism and found that the polymeric immunoglobulin receptor (pIgR) was abundant in exosomes derived from advanced HCC patients. These exosomes were primarily secreted by tumor cells. When recipient HCC cells took up these exosomes, β-catenin was transferred from the cytoplasm to the nucleus, which was closely related to the activation of PDK1/Akt/GSK-3β signaling. These exosomes ultimately enabled the recipient cells to acquire stem cell properties and enhance their invasion and metastasis abilities ^[15].

Among the many characteristics of cancers, abnormal sialylation has often been found to be important for the progression of tumors ^[16]. Wang et al. discovered that when α2,6-sialyltransferase I (ST6Gal-I) was silenced, the expression level of CD63, a regulator of exosome production and secretion, decreased. The level of α2,6-sialylated glycoconjugates on the surface of HCC-derived exosomes also decreased, reducing the internalization of exosomes by recipient cells. Furthermore, silencing of this molecule could attenuate the highly metastatic attributes of HCC-derived exosomes on the malignant biological behavior of low metastatic HCC cells, related to the suppressed function of highly metastatic HCC-derived exosomes, resulting in the failure of Akt/GSK-3β/β-catenin signaling and JNK1/2 signaling ^[17].

Table 1. EVs derived from HCC cells.

Molecules	Origin	Recipient Cells	Effects on Cell Behaviors	Mechanisms	References
MiR-1273f	Hypoxic HCC cells	Normoxic HCC cells	Promote proliferation, migration, invasion, and EMT	Upregulate LHX6/β-catenin	^[5]
MiR-25	High-metastatic HCC cells	Low-metastatic HCC cells	Reduce apoptosis and promote proliferation, migration, and invasion	Upregulate SIK1/β-catenin	^[13]
DDX55	HCC cells	HCC cells	Promote cell cycle progression and EMT.	Upregulate PI3K/Akt/GSK-3β/β-catenin	^[14]
		Endothelial cells	Promote angiogenesis	Upregulate PI3K/Akt/GSK-3β/β-catenin	^[14]
PIgR	Advanced HCC cells	Early HCC cells	Acquire stem cell properties and promote migration and invasion	Upregulate PDK1/Akt/GSK-3β/β-catenin	^[15]
Not mentioned	High-metastatic HCC cells	Low-metastatic HCC cells	Promote proliferation and migration	Upregulate Akt/GSK-3β/β-catenin and JNK1/2 signaling	^[17]

3. EVs Modulate Wnt Signaling through Transport between HCC and Stromal Cells and between Different Types of Stromal Cells

In addition to transferring cargos between tumor cells, EVs also act as a bridge between tumor cells and stromal cells and even between different types of stromal cells (Table 2). CAFs are important components of TME and are important for cancer progression and resisting treatment. Qin et al. discovered that Gremlin 1 was highly expressed in CAF-derived exosomes, which could be transferred into HCC cells to promote invasion, migration, and EMT of the recipient cells by activating Wnt/β-catenin signaling. As EMT is closely related to sorafenib resistance, they also investigated the effect of exosome-mediated Gremlin 1 transfer on the sensitivity of HCC cells to sorafenib. Their results indicated that HCC cells were less sensitive to sorafenib after exosome treatment through a similar mechanism, as described above ^[18]. Additionally, another study found that the expression of miR-320a notably decreased in HCC tissues and liver cancer cell lines. Lu et al. found that miR-320a overexpression in the HepG2 cells exhibited a marked inhibitory effect on cell proliferation. Mechanically, miR-320a exerted its tumor-suppressive function via downregulating the Wnt/β-catenin signaling pathway. However, in this study, for the first time, miR-320a was reported as a negative regulator of β-catenin ^[19]. Additionally, Zhang et al. found a significant reduction in the miR-320a expression in CAF-derived exosomes. CAF-mediated HCC tumor progression is partially related to the loss of miR-320a in the exosomes of CAFs, and transferring stromal cell-derived miR-320a might be a potential treatment option against HCC progression ^[20].

Macrophages are an important part of immune cells and mainly include two subtypes, namely: M1 type and M2 type. Among them, the M1 type plays a tumor suppressor role, whereas the M2 type has tumor-promoting properties, TAMs, with the M2 phenotype, in many tumors associated with malignant tumor progression ^[21]^[22]. Liu et al. found that miR-92a-2-5p is highly expressed in M2 macrophages and can be secreted into exosomes. When the exosomes were used to treat HCC cells, they found that the invasive ability of the recipient cells was enhanced. Then they explored the mechanism and observed reduced androgen receptor (AR) expression in recipient cells caused by the inhibition of AR mRNA translation by miR-92a-2-5p. The PHLPP/p-AKT/β-catenin signaling was altered by miR-92a-2-5p/AR axis ^[23]. Numerous studies have confirmed the association of tumor immune escape with CD8+ T cell dysfunction and severe depletion ^[24]^[25]^[26]. Pu et al. found increased expression of miR-21-5p in M2 macrophage-derived exosomes. After CD8+ T cells were treated with these exosomes, the levels of CD8+ T cell surface exhaustion markers, such as PD-1 and T cell immunoglobulin and mucin domain-containing protein 3, were significantly increased, and that of tumor suppressor factors, such as interferon-γ, interleukin-2, and tumor necrosis factor-α, were reduced. In animal experiments, it was found that exosomes can promote HCC tumorigenesis and malignant behavior and reduce the infiltration of CD8+ T cells in HCC tissues. Mechanistically, miR-21-5p acted mainly by binding to YOD1 mRNA, reducing YOD1 level, and thereby activating YAP/β-catenin signaling ^[27]. Previous studies had found that the activity of YOD1 was essential for antigen presentation, which was also the key associated with the effective functioning of antigen-specific CD8+ T cells ^[28]. In other tumor types, YAP has been found to induce the expression and secretion of multiple chemokines, which recruits myeloid-derived suppressor cells (MDSCs) and inhibits the function of cytotoxic T lymphocytes (CTLs), thereby promoting the formation of immunosuppressive TME ^[29]^[30].

Table 2. EVs derived from CAFs and M2 macrophages.

Molecules	Origin	Recipient Cells	Effects on Cell Behaviors	Mechanisms	References
Gremlin 1	CAFs	HCC cells	Promote migration, invasion, and EMT and reduce sensitivity to sorafenib	Upregulate Wnt/β-catenin	^[18]
miR-320a	CAFs	HCC cells	Inhibit proliferation	Downregulate Wnt/β-catenin	^[19]^[20]
MiR-92a-2-5p	M2 macrophages	HCC cells	Promote invasion	Upregulate PHLPP/p-AKT/β-catenin	^[23]
MiR-21-5p	M2 macrophages	CD8+ T cells	Induce exhaustion and reduce intratumoral immune infiltration	Upregulate YAP/β-catenin	^[27]

4. EVs Modulate β-Catenin Signaling in HCC by Altering the Cellular Localization of β-Catenin

Previous studies showed that the cellular localization of β-catenin was closely related to its function. When accumulated in the nucleus, it promoted EMT by mediating the expression of target genes. However, when localized on the plasma membrane (PM), it interacted with E-cadherin to increase cell-to-cell adhesion ^[31]^[32]. Several studies have found that EVs alter the cellular localization of β-catenin, which modulates β-catenin signaling in HCC (Table 3). Han et al. found that Vps4A overexpression could mediate β-catenin relocalization, promoting β-catenin expression on PM and secreting it out of the cell through exosomes, thereby reducing nuclear β-catenin level, which downregulated β-catenin signaling and suppressed EMT ^[33]. Then the research group found a similar phenomenon on another molecule. They found that exosomes derived from p62-overexpressing HCC cells can be taken up by p62-low-expressing HCC cells, following which p62 increased intracellular GSK3β levels, finally promoting β-catenin degradation. Unexpectedly, they observed that high levels of p62 promoted the malignant phenotype of HCC, including cell proliferation, migration, and invasion. This may be related to the p62-mediated extracellular secretion of exosome-coated β-catenin ^[34].

Table 3. EVs alter the cellular localization of β-catenin.

Molecules	Origin	Recipient Cells	Effects on Cell Behaviors	Mechanisms	References
Vps4A			Reduce EMT	Regulate cellular localization of β-catenin	^[33]
p62			Promote proliferation, migration, and invasion	Regulate cellular localization of β-catenin	^[34]

References

Luga, V.; Zhang, L.; Viloria-Petit, A.M.; Ogunjimi, A.A.; Inanlou, M.R.; Chiu, E.; Buchanan, M.; Hosein, A.N.; Basik, M.; Wrana, J.L. Exosomes Mediate Stromal Mobilization of Autocrine Wnt-PCP Signaling in Breast Cancer Cell Migration. Cell 2012, 151, 1542–1556.
Qiu, J.-J.; Sun, S.-G.; Tang, X.-Y.; Lin, Y.-Y.; Hua, K.-Q. Extracellular vesicular Wnt7b mediates HPV E6-induced cervical cancer angiogenesis by activating the β-catenin signaling pathway. J. Exp. Clin. Cancer Res. 2020, 39, 1–17.
Azad, M.B.; Chen, Y.; Henson, E.S.; Cizeau, J.; McMillan-Ward, E.; Israels, S.J.; Gibson, S.B. Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy 2008, 4, 195–204.
Henze, A.-T.; Mazzone, M. The impact of hypoxia on tumor-associated macrophages. J. Clin. Investig. 2016, 126, 3672–3679.
Yu, Y.; Min, Z.; Zhihang, Z.; Linhong, M.; Tao, R.; Yan, L.; Song, H. Hypoxia-induced exosomes promote hepatocellular carcinoma proliferation and metastasis via miR-1273f transfer. Exp. Cell Res. 2019, 385, 111649.
Pastushenko, I.; Blanpain, C. EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2019, 29, 212–226.
Hu, Z.; Xie, L. LHX6 inhibits breast cancer cell proliferation and invasion via repression of the Wnt/β-catenin signaling pathway. Mol. Med. Rep. 2015, 12, 4634–4639.
Yan, L.; Cai, K.; Sun, K.; Gui, J.; Liang, J. MiR-1290 promotes proliferation, migration, and invasion of glioma cells by targeting LHX6. J. Cell. Physiol. 2017, 233, 6621–6629.
Yang, J.; Han, F.; Liu, W.; Zhang, M.; Huang, Y.; Hao, X.; Jiang, X.; Yin, L.; Chen, H.; Cao, J.; et al. LHX6, An Independent Prognostic Factor, Inhibits Lung Adenocarcinoma Progression through Transcriptional Silencing of β-catenin. J. Cancer 2017, 8, 2561–2574.
Yang, B.; Feng, X.; Liu, H.; Tong, R.; Wu, J.; Li, C.; Yu, H.; Chen, Y.; Cheng, Q.; Chen, J.; et al. High-metastatic cancer cells derived exosomal miR92a-3p promotes epithelial-mesenchymal transition and metastasis of low-metastatic cancer cells by regulating PTEN/Akt pathway in hepatocellular carcinoma. Oncogene 2020, 39, 6529–6543.
Li, R.; Wang, Y.; Zhang, X.; Feng, M.; Ma, J.; Li, J.; Yang, X.; Fang, F.; Xia, Q.; Zhang, Z.; et al. Exosome-mediated secretion of LOXL4 promotes hepatocellular carcinoma cell invasion and metastasis. Mol. Cancer 2019, 18, 18.
Wang, S.; Chen, G.; Lin, X.; Xing, X.; Cai, Z.; Liu, X.; Liu, J. Role of exosomes in hepatocellular carcinoma cell mobility alteration. Oncol. Lett. 2017, 14, 8122–8131.
Fu, X.; Tang, Y.; Wu, W.; Ouyang, Y.; Tan, D.; Huang, Y. Exosomal microRNA-25 released from cancer cells targets SIK1 to promote hepatocellular carcinoma tumorigenesis. Dig. Liver Dis. 2021, 54, 954–963.
Yu, B.; Zhou, S.; Long, D.; Ning, Y.; Yao, H.; Zhou, E.; Wang, Y. DDX55 promotes hepatocellular carcinoma progression by interacting with BRD4 and participating in exosome-mediated cell-cell communication. Cancer Sci. 2022, 113, 3002–3017.
Tey, S.K.; Wong, S.W.K.; Chan, J.Y.T.; Mao, X.; Ng, T.H.; Yeung, C.L.S.; Leung, Z.; Fung, H.L.; Tang, A.H.N.; Wong, D.K.H.; et al. Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma. J. Hepatol. 2021, 76, 883–895.
Dall’Olio, F.; Chiricolo, M. Sialyltransferases in cancer. Glycoconj. J. 2001, 18, 841–850.
Wang, L.; Chen, X.; Wang, L.; Wang, S.; Li, W.; Liu, Y.; Zhang, J. Knockdown of ST6Gal-I expression in human hepatocellular carcinoma cells inhibits their exosome-mediated proliferation- and migration-promoting effects. IUBMB Life 2021, 73, 1378–1391.
Qin, W.; Wang, L.; Tian, H.; Wu, X.; Xiao, C.; Pan, Y.; Fan, M.; Tai, Y.; Liu, W.; Zhang, Q.; et al. CAF-derived exosomes transmitted Gremlin-1 promotes cancer progression and decreases the sensitivity of hepatoma cells to sorafenib. Mol. Carcinog. 2022, 61, 764–775.
Lu, C.; Liao, Z.; Cai, M.; Zhang, G. MicroRNA-320a downregulation mediates human liver cancer cell proliferation through the Wnt/β-catenin signaling pathway. Oncol. Lett. 2016, 13, 573–578.
Zhang, Z.; Li, X.; Sun, W.; Yue, S.; Yang, J.; Li, J.; Ma, B.; Wang, J.; Yang, X.; Pu, M.; et al. Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis. Cancer Lett. 2017, 397, 33–42.
Gordon, S.; Martinez, F.O. Alternative Activation of Macrophages: Mechanism and Functions. Immunity 2010, 32, 593–604.
Talmadge, J.E.; Donkor, M.; Scholar, E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007, 26, 373–400.
Liu, G.; Ouyang, X.; Sun, Y.; Xiao, Y.; You, B.; Gao, Y.; Yeh, S.; Li, Y.; Chang, C. The miR-92a-2-5p in exosomes from macrophages increases liver cancer cells invasion via altering the AR/PHLPP/p-AKT/β-catenin signaling. Cell Death Differ. 2020, 27, 3258–3272.
Zheng, C.; Zheng, L.; Yoo, J.-K.; Guo, H.; Zhang, Y.; Guo, X.; Kang, B.; Hu, R.; Huang, J.Y.; Zhang, Q.; et al. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell 2017, 169, 1342–1356.
Ma, J.; Zheng, B.; Goswami, S.; Meng, L.; Zhang, D.; Cao, C.; Li, T.; Zhu, F.; Ma, L.; Zhang, Z.; et al. PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma. J. Immunother. Cancer 2019, 7, 1–15.
Wherry, E.J.; Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 2015, 15, 486–499.
Pu, J.; Xu, Z.; Nian, J.; Fang, Q.; Yang, M.; Huang, Y.; Li, W.; Bin Ge, B.; Wang, J.; Wei, H. M2 macrophage-derived extracellular vesicles facilitate CD8+T cell exhaustion in hepatocellular carcinoma via the miR-21-5p/YOD1/YAP/β-catenin pathway. Cell Death Discov. 2021, 7, 182.
Sehrawat, S.; Koenig, P.-A.; Kirak, O.; Schlieker, C.; Fankhauser, M.; Ploegh, H.L. A catalytically inactive mutant of the deubiquitylase YOD-1 enhances antigen cross-presentation. Blood 2013, 121, 1145–1156.
Wang, G.; Lu, X.; Dey, P.; Deng, P.; Wu, C.C.; Jiang, S.; Fang, Z.; Zhao, K.; Konaparthi, R.; Hua, S.; et al. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discov. 2016, 6, 80–95.
Murakami, S.; Shahbazian, D.; Surana, R.; Zhang, W.; Chen, H.; Graham, G.T.; White, S.M.; Weiner, L.M.; Yi, C. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene 2017, 36, 1232–1244.
Heuberger, J.; Birchmeier, W. Interplay of Cadherin-Mediated Cell Adhesion and Canonical Wnt Signaling. Cold Spring Harb. Perspect. Biol. 2010, 2, a002915.
McCrea, P.D.; Maher, M.T.; Gottardi, C.J. Nuclear Signaling from Cadherin Adhesion Complexes. Curr. Top. Dev. Biol. 2015, 112, 129–196.
Han, Q.; Lv, L.; Wei, J.; Lei, X.; Lin, H.; Li, G.; Cao, J.; Xie, J.; Yang, W.; Wu, S.; et al. Vps4A mediates the localization and exosome release of β-catenin to inhibit epithelial-mesenchymal transition in hepatocellular carcinoma. Cancer Lett. 2019, 457, 47–59.
Yang, W.; Wei, J.; Lv, L.; Xie, J.; Li, A.; Zheng, Z.; Zhuo, W.; Liu, P.; Min, J. p62 Promotes Malignancy of Hepatocellular Carcinoma by Regulating the Secretion of Exosomes and the Localization of β-Catenin. Front. Biosci. 2022, 27, 89.

© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Biochemistry & Molecular Biology

Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Risheng He

Yi Xu

Liang Yu

Nanfeng Meng

Hang Wang

Yunfu Cui

Judy Wai Ping Yam

View Times: 281

Update Date: 24 Apr 2023

Table of Contents

Video Upload Options

Confirm